Loading...
Tumor LAG‐3 and NY‐ESO‐1 expression predict durable clinical benefits of immune checkpoint inhibitors in advanced non‐small cell lung cancer
BACKGROUND: Immune checkpoint inhibitors (ICIs) are an established treatment for non‐small cell lung cancer (NSCLC) that have demonstrated durable clinical benefits (DCBs). Previous studies have suggested NY‐ESO‐1 and LAG‐3 to be surrogate markers of ICI responses in NSCLC; therefore, we explored th...
Na minha lista:
| Udgivet i: | Thorac Cancer |
|---|---|
| Main Authors: | , , , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
John Wiley & Sons Australia, Ltd
2021
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7919166/ https://ncbi.nlm.nih.gov/pubmed/33458968 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1759-7714.13834 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|